← Leaderboards
Guatam Chatnekar
Xequel Bio, Inc.
$6,620,728
Attributed
$6,620,728
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2021–24$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
Funding mix
By agency
NIH$6,620,728 · 1
By mechanism
N01$6,620,728 · 1
Top collaborators
No co-investigators on record.
Most similar at Xequel Bio, Inc.
Same institution · by research overlap
- Gautam Sudhir Ghatnekar$7,871,466
- Christina Grek$5,343,622
Others in their field
Other Emerging Leaders on “Validation”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$159,061,147
- Yunda Huang · Fred Hutchinson Cancer Center$72,541,909
- Ted Ross · University Of Georgia$59,913,818
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
ValidationAnimal RuleAnti-Inflammatory AgentsCutaneousEfficacy StudyEfficacy ValidationMedical CountermeasurePeptidesPorcine ModelPropertyRadiation Dose UnitRadiation InjuriesSafetySafety StudySkin Wound HealingTopical ApplicationAcceleration
Grant awards (4)
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$137,994
N01 · FY2024 · AI · contact PI
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$2,131,855
N01 · FY2023 · AI · contact PI
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$2,657,130
N01 · FY2022 · AI · contact PI
GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY$1,693,749
N01 · FY2021 · AI · contact PI